Antibody responses to viral infections: a structural perspective across three different enveloped viruses (original) (raw)

• White, J. M. & Whittaker, G. R. Fusion of enveloped viruses in endosomes. Traffic 17, 593–614 (2016).
  CAS PubMed PubMed Central Google Scholar
• Harrison, S. C. Viral membrane fusion. Virology 479–480, 498–507 (2015).
  PubMed Google Scholar
• Harris, L. J., Larson, S. B., Hasel, K. W. & McPherson, A. Refined structure of an intact IgG2a monoclonal antibody. Biochemistry 36, 1581–1597 (1997).
  CAS PubMed Google Scholar
• Harris, L. J., Skaletsky, E. & McPherson, A. Crystallographic structure of an intact IgG1 monoclonal antibody. J. Mol. Biol. 275, 861–872 (1998).
  CAS PubMed Google Scholar
• Saphire, E. O. et al. Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Science 293, 1155–1159 (2001).
  CAS PubMed Google Scholar
• Scapin, G. et al. Structure of full-length human anti-PD1 therapeutic IgG4 antibody pembrolizumab. Nat. Struct. Mol. Biol. 22, 953–958 (2015).
  CAS PubMed Google Scholar
• Stanfield, R. L. & Wilson, I. A. Antibody Structure. Microbiol. Spectr. 2, AID-0012-2013 (2014).
• Wilson, I. A. & Stanfield, R. L. Antibody-antigen interactions: new structures and new conformational changes. Curr. Opin. Struct. Biol. 4, 857–867 (1994).
  CAS PubMed Google Scholar
• Bullough, P. A., Hughson, F. M., Skehel, J. J. & Wiley, D. C. Structure of influenza haemagglutinin at the pH of membrane fusion. Nature 371, 37–43 (1994).
  CAS PubMed Google Scholar
• Wilson, I. A., Skehel, J. J. & Wiley, D. C. Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution. Nature 289, 366–373 (1981).
  CAS PubMed Google Scholar
• Julien, J. P. et al. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 342, 1477–1483 (2013).
  CAS PubMed Google Scholar
• Lyumkis, D. et al. Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science 342, 1484–1490 (2013).
  CAS PubMed PubMed Central Google Scholar
• Chan, D. C., Fass, D., Berger, J. M. & Kim, P. S. Core structure of gp41 from the HIV envelope glycoprotein. Cell 89, 263–273 (1997).
  CAS PubMed Google Scholar
• Weissenhorn, W., Dessen, A., Harrison, S. C., Skehel, J. J. & Wiley, D. C. Atomic structure of the ectodomain from HIV-1 gp41. Nature 387, 426–430 (1997).
  CAS PubMed Google Scholar
• Lee, J. E. et al. Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature 454, 177–182 (2008).
  CAS PubMed PubMed Central Google Scholar
• Weissenhorn, W., Carfi, A., Lee, K. H., Skehel, J. J. & Wiley, D. C. Crystal structure of the Ebola virus membrane fusion subunit, GP2, from the envelope glycoprotein ectodomain. Mol. Cell 2, 605–616 (1998).
  CAS PubMed Google Scholar
• Cook, J. D. & Lee, J. E. The secret life of viral entry glycoproteins: moonlighting in immune evasion. PLoS Pathog. 9, e1003258 (2013).
  CAS PubMed PubMed Central Google Scholar
• Tate, M. D. et al. Playing hide and seek: how glycosylation of the influenza virus hemagglutinin can modulate the immune response to infection. Viruses 6, 1294–1316 (2014).
  PubMed PubMed Central Google Scholar
• Wu, N. C. & Wilson, I. A. A Perspective on the structural and functional constraints for immune evasion: insights from influenza virus. J. Mol. Biol. 429, 2694–2709 (2017).
  CAS PubMed PubMed Central Google Scholar
• Crispin, M., Ward, A. B. & Wilson, I. A. Structure and immune recognition of the HIV glycan shield. Ann. Rev. Biophys. 47, 499–523 (2018).
  CAS Google Scholar
• Cao, L. et al. Global site-specific N-glycosylation analysis of HIV envelope glycoprotein. Nat. Commun. 8, 14954 (2017).
  CAS PubMed PubMed Central Google Scholar
• Lee, J. H., de Val, N., Lyumkis, D. & Ward, A. B. Model building and refinement of a natively glycosylated HIV-1 Env protein by high-resolution cryoelectron microscopy. Structure 23, 1943–1951 (2015).
  CAS PubMed PubMed Central Google Scholar
• Ekiert, D. C. et al. Antibody recognition of a highly conserved influenza virus epitope. Science 324, 246–251 (2009).
  CAS PubMed PubMed Central Google Scholar
• Flyak, A. I. et al. Mechanism of human antibody-mediated neutralization of Marburg virus. Cell 160, 893–903 (2015).
  CAS PubMed PubMed Central Google Scholar
• Julien, J. P. et al. Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. Proc. Natl Acad. Sci. USA 110, 4351–4356 (2013).
  CAS PubMed PubMed Central Google Scholar
• Kong, L. et al. Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nat. Struct. Mol. Biol. 20, 796–803 (2013).
  CAS PubMed PubMed Central Google Scholar
• Murin, C. D. et al. Structure of 2G12 Fab2 in complex with soluble and fully glycosylated HIV-1 Env by negative-stain single-particle electron microscopy. J. Virol. 88, 10177–10188 (2014).
  PubMed PubMed Central Google Scholar
• Williams, K. L. et al. Superinfection drives HIV neutralizing antibody responses from several B cell lineages that contribute to a polyclonal repertoire. Cell Rep. 23, 682–691 (2018).
  CAS PubMed PubMed Central Google Scholar
• Bianchi, M. et al. Electron-microscopy-based epitope mapping defines specificities of polyclonal antibodies elicited during HIV-1 BG505 envelope trimer immunization. Immunity 49, 288–300 (2018).
  CAS PubMed PubMed Central Google Scholar
• Ozorowski, G. et al. Open and closed structures reveal allostery and pliability in the HIV-1 envelope spike. Nature 547, 360–363 (2017).
  CAS PubMed PubMed Central Google Scholar
• Georgiev, I. S., Gordon Joyce, M., Zhou, T. & Kwong, P. D. Elicitation of HIV-1-neutralizing antibodies against the CD4-binding site. Curr. Opin. HIV AIDS 8, 382–392 (2013).
  CAS PubMed PubMed Central Google Scholar
• Zhou, T. et al. Structural Repertoire of HIV-1-neutralizing antibodies targeting the CD4 supersite in 14 donors. Cell 161, 1280–1292 (2015).
  CAS PubMed PubMed Central Google Scholar
• Xu, R. et al. A recurring motif for antibody recognition of the receptor-binding site of influenza hemagglutinin. Nat. Struct. Mol. Biol. 20, 363–370 (2013).
  CAS PubMed PubMed Central Google Scholar
• Garcia-Sastre, A. Influenza virus receptor specificity: disease and transmission. Am. J. Pathol. 176, 1584–1585 (2010).
  PubMed PubMed Central Google Scholar
• Stevens, J. et al. Structure and receptor specificity of the hemagglutinin from an H5N1 influenza virus. Science 312, 404–410 (2006).
  CAS PubMed Google Scholar
• Wu, N. C. et al. A complex epistatic network limits the mutational reversibility in the influenza hemagglutinin receptor-binding site. Nat. Commun. 9, 1264 (2018).
  PubMed PubMed Central Google Scholar
• Wu, N. C. et al. Diversity of functionally permissive sequences in the receptor-binding site of influenza hemagglutinin. Cell Host Microbe 22, 247–248 (2017).
  CAS PubMed PubMed Central Google Scholar
• Lee, P. S. et al. Receptor mimicry by antibody F045–092 facilitates universal binding to the H3 subtype of influenza virus. Nat. Commun. 5, 3614 (2014).
  PubMed Google Scholar
• Wu, N. C. et al. In vitro evolution of an influenza broadly neutralizing antibody is modulated by hemagglutinin receptor specificity. Nat. Commun. 8, 15371 (2017).
  CAS PubMed PubMed Central Google Scholar
• Julien, J. P., Lee, P. S. & Wilson, I. A. Structural insights into key sites of vulnerability on HIV-1 Env and influenza HA. Immunol. Rev. 250, 180–198 (2012).
  PubMed PubMed Central Google Scholar
• Laursen, N. S. & Wilson, I. A. Broadly neutralizing antibodies against influenza viruses. Antivir. Res. 98, 476–483 (2013).
  CAS PubMed Google Scholar
• Lee, P. S. & Wilson, I. A. Structural characterization of viral epitopes recognized by broadly cross-reactive antibodies. Curr. Top. Microbiol. 386, 323–341 (2015).
  CAS Google Scholar
• Bornholdt, Z. A. et al. Host-primed Ebola virus GP exposes a hydrophobic NPC1 receptor-binding pocket, revealing a target for broadly neutralizing antibodies. mBio 7, e02154–15 (2016).
  CAS PubMed PubMed Central Google Scholar
• Chandran, K., Sullivan, N. J., Felbor, U., Whelan, S. P. & Cunningham, J. M. Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. Science 308, 1643–1645 (2005).
  CAS PubMed PubMed Central Google Scholar
• Miller, E. H. et al. Ebola virus entry requires the host-programmed recognition of an intracellular receptor. EMBO J. 31, 1947–1960 (2012).
  CAS PubMed PubMed Central Google Scholar
• Gnirss, K. et al. Cathepsins B and L activate Ebola but not Marburg virus glycoproteins for efficient entry into cell lines and macrophages independent of TMPRSS2 expression. Virology 424, 3–10 (2012).
  CAS PubMed Google Scholar
• King, L. B. et al. The Marburgvirus-neutralizing human monoclonal antibody MR191 targets a conserved site to block virus receptor binding. Cell Host Microbe 23, 101–109 (2018).
  CAS PubMed PubMed Central Google Scholar
• Hashiguchi, T. et al. Structural basis for Marburg virus neutralization by a cross-reactive human antibody. Cell 160, 904–912 (2015).
  CAS PubMed PubMed Central Google Scholar
• Wang, H. et al. Ebola viral glycoprotein bound to its endosomal receptor niemann-pick C1. Cell 164, 258–268 (2016).
  CAS PubMed PubMed Central Google Scholar
• Lin, Y. P. et al. Evolution of the receptor binding properties of the influenza A(H3N2) hemagglutinin. Proc. Natl Acad. Sci. USA 109, 21474–21479 (2012).
  CAS PubMed PubMed Central Google Scholar
• Ekiert, D. C. et al. Cross-neutralization of influenza A viruses mediated by a single antibody loop. Nature 489, 526–532 (2012).
  CAS PubMed PubMed Central Google Scholar
• Lee, P. S. et al. Heterosubtypic antibody recognition of the influenza virus hemagglutinin receptor binding site enhanced by avidity. Proc. Natl Acad. Sci. USA 109, 17040–17045 (2012).
  CAS PubMed PubMed Central Google Scholar
• Whittle, J. R. et al. Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. Proc. Natl Acad. Sci. USA 108, 14216–14221 (2011).
  CAS PubMed PubMed Central Google Scholar
• Schmidt, A. G. et al. Viral receptor-binding site antibodies with diverse germline origins. Cell 161, 1026–1034 (2015).
  CAS PubMed PubMed Central Google Scholar
• Kwong, P. D. et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393, 648–659 (1998).
  CAS PubMed PubMed Central Google Scholar
• Garrett, T. P., Wang, J., Yan, Y., Liu, J. & Harrison, S. C. Refinement and analysis of the structure of the first two domains of human CD4. J. Mol. Biol. 234, 763–778 (1993).
  CAS PubMed Google Scholar
• Wu, X. et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329, 856–861 (2010).
  CAS PubMed PubMed Central Google Scholar
• Zhou, T. et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329, 811–817 (2010).
  CAS PubMed PubMed Central Google Scholar
• Zhou, T. et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445, 732–737 (2007).
  CAS PubMed PubMed Central Google Scholar
• Bale, S. et al. Structural basis for differential neutralization of ebolaviruses. Viruses 4, 447–470 (2012).
  CAS PubMed PubMed Central Google Scholar
• Dias, J. M. et al. A shared structural solution for neutralizing ebolaviruses. Nat. Struct. Mol. Biol. 18, 1424–1427 (2011).
  CAS PubMed PubMed Central Google Scholar
• Lee, J. E. & Saphire, E. O. Ebolavirus glycoprotein structure and mechanism of entry. Future Virol. 4, 621–635 (2009).
  CAS PubMed PubMed Central Google Scholar
• Crowe, J. E. Jr. Principles of broad and potent antiviral human antibodies: insights for vaccine design. Cell Host Microbe 22, 193–206 (2017).
  CAS PubMed PubMed Central Google Scholar
• Hashem, A. M. et al. Universal antibodies against the highly conserved influenza fusion peptide cross-neutralize several subtypes of influenza A virus. Biochem. Bioph. Res. Co. 403, 247–251 (2010).
  CAS Google Scholar
• Murin, C. D., Bruhn, J. F., Bornholdt, Z. A., Copps, J., Stanfield, R. & Ward, A. B. Structural basis of pan-ebolavirus neutralization by an antibody targeting the glycoprotein fusion loop. Cell Rep. 24, 2723–2732 (2018).
  CAS PubMed PubMed Central Google Scholar
• van Gils, M. J. et al. An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability. Nat. Microbiol. 2, 16199 (2016).
  PubMed PubMed Central Google Scholar
• Kong, R. et al. Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody. Science 352, 828–833 (2016).
  CAS PubMed PubMed Central Google Scholar
• Xu, K. et al. Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1. Nat. Med. 24, 857–867 (2018).
  CAS PubMed PubMed Central Google Scholar
• Kallewaard, N. L. et al. Structure and function analysis of an antibody recognizing all Influenza A subtypes. Cell 166, 596–608 (2016).
  CAS PubMed PubMed Central Google Scholar
• Prabhu, N. et al. Monoclonal antibodies against the fusion peptide of hemagglutinin protect mice from lethal influenza A virus H5N1 infection. J. Virol. 83, 2553–2562 (2009).
  CAS PubMed Google Scholar
• Zhao, X. et al. Immunization-elicited broadly protective antibody reveals Ebolavirus fusion loop as a site of vulnerability. Cell 169, 891–904 (2017).
  CAS PubMed PubMed Central Google Scholar
• Furuyama, W. et al. Discovery of an antibody for pan-ebolavirus therapy. Sci. Rep. 6, 20514 (2016).
  CAS PubMed PubMed Central Google Scholar
• Wec, A. Z. et al. Antibodies from a human survivor define sites of vulnerability for broad protection against Ebolaviruses. Cell 169, 878–890 (2017).
  CAS PubMed PubMed Central Google Scholar
• Zhu, P. et al. Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions. Proc. Natl Acad. Sci. USA 100, 15812–15817 (2003).
  CAS PubMed PubMed Central Google Scholar
• Zhu, P. et al. Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature 441, 847–852 (2006).
  CAS PubMed Google Scholar
• Lee, J. H., Ozorowski, G. & Ward, A. B. Cryo-EM structure of a native, fully glycosylated, cleaved HIV-1 envelope trimer. Science 351, 1043–1048 (2016).
  CAS PubMed PubMed Central Google Scholar
• Huang, J. et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 491, 406–412 (2012).
  CAS PubMed PubMed Central Google Scholar
• Cardoso, R. M. et al. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity 22, 163–173 (2005).
  CAS PubMed Google Scholar
• Flyak, A. I. et al. Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2-MPER region. Nat. Microbiol. 3, 670–677 (2018).
  CAS PubMed PubMed Central Google Scholar
• Krammer, F. & Palese, P. Influenza virus hemagglutinin stalk-based antibodies and vaccines. Curr. Opin. Virol. 3, 521–530 (2013).
  CAS PubMed PubMed Central Google Scholar
• Dreyfus, C., Ekiert, D. C. & Wilson, I. A. Structure of a classical broadly neutralizing stem antibody in complex with a pandemic H2 influenza virus hemagglutinin. J. Virol. 87, 7149–7154 (2013).
  CAS PubMed PubMed Central Google Scholar
• Khanna, M., Sharma, S., Kumar, B. & Rajput, R. Protective immunity based on the conserved hemagglutinin stalk domain and its prospects for universal influenza vaccine development. Biomed. Res. Int. 2014, 546274 (2014).
  PubMed PubMed Central Google Scholar
• Erbelding, E. J. et al. A universal Influenza vaccine: the strategic plan for the National Institute of Allergy and Infectious Diseases. J. Infect. Dis. 218, 347–354 (2018).
  CAS PubMed PubMed Central Google Scholar
• Impagliazzo, A. et al. A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. Science 349, 1301–1306 (2015).
  CAS PubMed Google Scholar
• Krammer, F., Garcia-Sastre, A. & Palese, P. Is it possible to develop a “universal” influenza virus vaccine? Potential target antigens and critical aspects for a universal influenza vaccine. Cold Spring Harb. Perspect. Biol. https://doi.org/10.1101/cshperspect.a028845 (2018).
  Article PubMed PubMed Central Google Scholar
• Krammer, F., Pica, N., Hai, R., Margine, I. & Palese, P. Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J. Virol. 87, 6542–6550 (2013).
  CAS PubMed PubMed Central Google Scholar
• Nachbagauer, R. et al. A universal influenza virus vaccine candidate confers protection against pandemic H1N1 infection in preclinical ferret studies. NPJ Vaccines 2, 26 (2017).
  PubMed PubMed Central Google Scholar
• Yassine, H. M. et al. Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nat. Med. 21, 1065–1070 (2015).
  CAS PubMed Google Scholar
• Irimia, A. et al. Lipid interactions and angle of approach to the HIV-1 viral membrane of broadly neutralizing antibody 10E8: Insights for vaccine and therapeutic design. PLoS Pathog. 13, e1006212 (2017).
  PubMed PubMed Central Google Scholar
• Irimia, A., Sarkar, A., Stanfield, R. L. & Wilson, I. A. Crystallographic identification of lipid as an integral component of the epitope of HIV broadly neutralizing antibody 4E10. Immunity 44, 21–31 (2016).
  CAS PubMed PubMed Central Google Scholar
• Friesen, R. H. et al. A common solution to group 2 influenza virus neutralization. Proc. Natl Acad. Sci. USA 111, 445–450 (2014).
  CAS PubMed Google Scholar
• Burton, D. R. Antibodies, viruses and vaccines. Nat. Rev. Immunol. 2, 706–713 (2002).
  CAS PubMed Google Scholar
• Burton, D. R. & Mascola, J. R. Antibody responses to envelope glycoproteins in HIV-1 infection. Nat. Immunol. 16, 571–576 (2015).
  CAS PubMed PubMed Central Google Scholar
• Burton, D. R., Poignard, P., Stanfield, R. L. & Wilson, I. A. Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science 337, 183–186 (2012).
  CAS PubMed PubMed Central Google Scholar
• Burton, D. R., Stanfield, R. L. & Wilson, I. A. Antibody vs. HIV in a clash of evolutionary titans. Proc. Natl Acad. Sci. USA 102, 14943–14948 (2005).
  CAS PubMed PubMed Central Google Scholar
• Caskey, M., Klein, F. & Nussenzweig, M. C. Broadly neutralizing antibodies for HIV-1 prevention or immunotherapy. N. Engl. J. Med. 375, 2019–2021 (2016).
  CAS PubMed Google Scholar
• Mouquet, H. et al. Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc. Natl Acad. Sci. USA 109, E3268–3277 (2012).
  CAS PubMed PubMed Central Google Scholar
• McLellan, J. S. et al. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 480, 336–343 (2011).
  CAS PubMed PubMed Central Google Scholar
• Julien, J. P. et al. Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans. PLoS Pathog. 9, e1003342 (2013).
  CAS PubMed PubMed Central Google Scholar
• Pejchal, R. et al. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 334, 1097–1103 (2011).
  CAS PubMed PubMed Central Google Scholar
• Calarese, D. A. et al. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 300, 2065–2071 (2003).
  CAS PubMed Google Scholar
• Stanfield, R. L., De Castro, C., Marzaioli, A. M., Wilson, I. A. & Pantophlet, R. Crystal structure of the HIV neutralizing antibody 2G12 in complex with a bacterial oligosaccharide analog of mammalian oligomannose. Glycobiology 25, 412–419 (2015).
  CAS PubMed Google Scholar
• Kwong, P. D. et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420, 678–682 (2002).
  CAS PubMed Google Scholar
• Lee, J. H. et al. A broadly neutralizing antibody targets the dynamic HIV envelope trimer apex via a long, rigidified, and anionic beta-hairpin structure. Immunity 46, 690–702 (2017).
  CAS PubMed PubMed Central Google Scholar
• Cale, E. M. et al. Virus-like particles identify an HIV V1V2 apex-binding neutralizing antibody that lacks a protruding loop. Immunity 46, 777–791 (2017).
  CAS PubMed PubMed Central Google Scholar
• Wang, H. et al. Asymmetric recognition of HIV-1 envelope trimer by V1V2 loop-targeting antibodies. eLife 6, e27389 (2017).
  PubMed PubMed Central Google Scholar
• Kashyap, A. K. et al. Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies. Proc. Natl Acad. Sci. USA 105, 5986–5991 (2008).
  CAS PubMed PubMed Central Google Scholar
• Lang, S. et al. Antibody 27F3 broadly targets influenza A group 1 and 2 hemagglutinins through a further variation in VH1–69 antibody orientation on the HA stem. Cell Rep. 20, 2935–2943 (2017).
  CAS PubMed PubMed Central Google Scholar
• Sui, J. et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat. Struct. Mol. Biol. 16, 265–273 (2009).
  CAS PubMed PubMed Central Google Scholar
• Throsby, M. et al. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS ONE 3, e3942 (2008).
  PubMed PubMed Central Google Scholar
• Lerner, R. A. Rare antibodies from combinatorial libraries suggests an S. O. S. component of the human immunological repertoire. Mol. Biosyst. 7, 1004–1012 (2011).
  CAS PubMed Google Scholar
• Lerner, R. A. Combinatorial antibody libraries: new advances, new immunological insights. Nat. Rev. Immunol. 16, 498–508 (2016).
  CAS PubMed Google Scholar
• Pallesen, J. et al. Structures of Ebola virus GP and sGP in complex with therapeutic antibodies. Nat. Microbiol. 1, 16128 (2016).
  CAS PubMed PubMed Central Google Scholar
• de La Vega, M. A., Wong, G., Kobinger, G. P. & Qiu, X. The multiple roles of sGP in Ebola pathogenesis. Viral Immunol. 28, 3–9 (2015).
  Google Scholar
• Bornholdt, Z. A. et al. Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak. Science 351, 1078–1083 (2016).
  CAS PubMed PubMed Central Google Scholar
• Flyak, A. I. et al. Cross-reactive and potent neutralizing antibody responses in human survivors of natural ebolavirus infection. Cell 164, 392–405 (2016).
  CAS PubMed PubMed Central Google Scholar
• Wilson, J. A. et al. Epitopes involved in antibody-mediated protection from Ebola virus. Science 287, 1664–1666 (2000).
  CAS PubMed Google Scholar
• Howell, K. A. et al. Cooperativity enables non-neutralizing antibodies to neutralize ebolavirus. Cell Rep. 19, 413–424 (2017).
  CAS PubMed PubMed Central Google Scholar
• Kwong, P. D. & Mascola, J. R. HIV-1 vaccines based on antibody identification, B cell ontogeny, and epitope structure. Immunity 48, 855–871 (2018).
  CAS PubMed Google Scholar
• Flynn, N. M. et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis. 191, 654–665 (2005).
  PubMed Google Scholar
• Pitisuttithum, P. et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J. Infect. Dis. 194, 1661–1671 (2006).
  CAS PubMed Google Scholar
• Dolin, R. et al. The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network. Ann. Intern. Med. 114, 119–127 (1991).
  CAS PubMed Google Scholar
• Cooney, E. L. et al. Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet 337, 567–572 (1991).
  CAS PubMed Google Scholar
• Burton, D. R. et al. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 5, 233–236 (2004).
  CAS PubMed Google Scholar
• Gonzalez, N. et al. Characterization of broadly neutralizing antibody responses to HIV-1 in a cohort of long term non-progressors. PLoS ONE 13, e0193773 (2018).
  PubMed PubMed Central Google Scholar
• Gray, E. S. et al. The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J. Virol. 85, 4828–4840 (2011).
  CAS PubMed PubMed Central Google Scholar
• Kelsoe, G. & Haynes, B. F. Host controls of HIV broadly neutralizing antibody development. Immunol. Rev. 275, 79–88 (2017).
  CAS PubMed PubMed Central Google Scholar
• Burton, D. R. et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266, 1024–1027 (1994).
  CAS PubMed Google Scholar
• Muster, T. et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 67, 6642–6647 (1993).
  CAS PubMed PubMed Central Google Scholar
• Trkola, A. et al. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70, 1100–1108 (1996).
  CAS PubMed PubMed Central Google Scholar
• Buchacher, A. et al. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res. Hum. Retrov. 10, 359–369 (1994).
  CAS Google Scholar
• Binley, J. M. et al. A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. J. Virol. 74, 627–643 (2000).
  CAS PubMed PubMed Central Google Scholar
• Sanders, R. W. et al. Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J. Virol. 76, 8875–8889 (2002).
  CAS PubMed PubMed Central Google Scholar
• Sanders, R. W. et al. A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog. 9, e1003618 (2013).
  CAS PubMed PubMed Central Google Scholar
• Sanders, R. W. & Moore, J. P. Native-like Env trimers as a platform for HIV-1 vaccine design. Immunol. Rev. 275, 161–182 (2017).
  CAS PubMed PubMed Central Google Scholar
• Sanders, R. W., Wilson, I. A. & Moore, J. P. HIV’s Achilles’ heel. Sci. Am. 315, 50–55 (2016).
  CAS PubMed Google Scholar
• Torrents de la Pena, A. et al. Improving the immunogenicity of native-like HIV-1 envelope trimers by hyperstabilization. Cell Rep. 20, 1805–1817 (2017).
  CAS PubMed PubMed Central Google Scholar
• Voss, J. E. et al. Elicitation of neutralizing antibodies targeting the V2 apex of the HIV envelope trimer in a wild-type animal model. Cell Rep. 21, 222–235 (2017).
  CAS PubMed PubMed Central Google Scholar
• de Taeye, S. W. et al. Immunogenicity of stabilized HIV-1 envelope trimers with reduced exposure of non-neutralizing epitopes. Cell 163, 1702–1715 (2015).
  PubMed PubMed Central Google Scholar
• Kulp, D. W. & Schief, W. R. Advances in structure-based vaccine design. Curr. Opin. Virol. 3, 322–331 (2013).
  CAS PubMed PubMed Central Google Scholar
• Kulp, D. W. et al. Structure-based design of native-like HIV-1 envelope trimers to silence non-neutralizing epitopes and eliminate CD4 binding. Nat. Commun. 8, 1655 (2017).
  PubMed PubMed Central Google Scholar
• Correia, B. E. et al. Proof of principle for epitope-focused vaccine design. Nature 507, 201–206 (2014).
  CAS PubMed PubMed Central Google Scholar
• Jardine, J. et al. Rational HIV immunogen design to target specific germline B cell receptors. Science 340, 711–716 (2013).
  CAS PubMed PubMed Central Google Scholar
• Jardine, J. G. et al. HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen. Science 351, 1458–1463 (2016).
  CAS PubMed PubMed Central Google Scholar
• Jardine, J. G. et al. HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen. Science 349, 156–161 (2015).
  CAS PubMed PubMed Central Google Scholar
• Correia, B. E. et al. Computational design of epitope-scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope. Structure 18, 1116–1126 (2010).
  CAS PubMed Google Scholar
• McLellan, J. S. et al. Design and characterization of epitope-scaffold immunogens that present the motavizumab epitope from respiratory syncytial virus. J. Mol. Biol. 409, 853–866 (2011).
  CAS PubMed PubMed Central Google Scholar
• Ofek, G. et al. Elicitation of structure-specific antibodies by epitope scaffolds. Proc. Natl Acad. Sci. USA 107, 17880–17887 (2010).
  CAS PubMed PubMed Central Google Scholar
• de Taeye, S. W., Moore, J. P. & Sanders, R. W. HIV-1 Envelope trimer design and immunization strategies to induce broadly neutralizing antibodies. Trends Immunol. 37, 221–232 (2016).
  PubMed PubMed Central Google Scholar
• Sanders, R. W. et al. HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers. Science 349, aac4223 (2015).
  PubMed PubMed Central Google Scholar
• Pauthner, M. et al. Elicitation of robust tier 2 neutralizing antibody responses in nonhuman primates by HIV envelope trimer immunization using optimized approaches. Immunity 46, 1073–1088 (2017).
  CAS PubMed PubMed Central Google Scholar
• Krammer, F. et al. Assessment of influenza virus hemagglutinin stalk-based immunity in ferrets. J. Virol. 88, 3432–3442 (2014).
  PubMed PubMed Central Google Scholar
• Krammer, F. et al. H3 stalk-based chimeric hemagglutinin influenza virus constructs protect mice from H7N9 challenge. J. Virol. 88, 2340–2343 (2014).
  PubMed PubMed Central Google Scholar
• Mallajosyula, V. V. et al. Influenza hemagglutinin stem-fragment immunogen elicits broadly neutralizing antibodies and confers heterologous protection. Proc. Natl Acad. Sci. USA 111, E2514–E2523 (2014).
  CAS PubMed PubMed Central Google Scholar
• Wohlbold, T. J. et al. Vaccination with soluble headless hemagglutinin protects mice from challenge with divergent influenza viruses. Vaccine 33, 3314–3321 (2015).
  CAS PubMed PubMed Central Google Scholar
• Hai, R. et al. Influenza viruses expressing chimeric hemagglutinins: globular head and stalk domains derived from different subtypes. J. Virol. 86, 5774–5781 (2012).
  CAS PubMed PubMed Central Google Scholar
• Goo, L., Chohan, V., Nduati, R. & Overbaugh, J. Early development of broadly neutralizing antibodies in HIV-1-infected infants. Nat. Med. 20, 655–658 (2014).
  CAS PubMed PubMed Central Google Scholar
• van den Kerkhof, T. L. et al. Early development of broadly reactive HIV-1 neutralizing activity in elite neutralizers. AIDS 28, 1237–1240 (2014).
  PubMed Google Scholar
• Sok, D. et al. Priming HIV-1 broadly neutralizing antibody precursors in human Ig loci transgenic mice. Science 353, 1557–1560 (2016).
  CAS PubMed PubMed Central Google Scholar
• Havenar-Daughton, C. et al. The human naive B cell repertoire contains distinct subclasses for a germline-targeting HIV-1 vaccine immunogen. Sci. Transl Med. 10, eaat0381 (2018).
  PubMed PubMed Central Google Scholar
• Havenar-Daughton, C., Abbott, R. K., Schief, W. R. & Crotty, S. When designing vaccines, consider the starting material: the human B cell repertoire. Curr. Opin. Immunol. 53, 209–216 (2018).
  CAS PubMed PubMed Central Google Scholar
• Arnaout, R. et al. High-resolution description of antibody heavy-chain repertoires in humans. PLoS ONE 6, e22365 (2011).
  CAS PubMed PubMed Central Google Scholar
• DeKosky, B. J. et al. In-depth determination and analysis of the human paired heavy- and light-chain antibody repertoire. Nat. Med. 21, 86–91 (2015).
  CAS PubMed Google Scholar
• Abbott, R. K. et al. Precursor frequency and affinity determine B cell competitive fitness in germinal centers, tested with germline-targeting HIV vaccine immunogens. Immunity 48, 133–146 (2018).
  CAS PubMed Google Scholar
• Havenar-Daughton, C. et al. Direct probing of germinal center responses reveals immunological features and bottlenecks for neutralizing antibody responses to HIV Env trimer. Cell Rep. 17, 2195–2209 (2016).
  CAS PubMed PubMed Central Google Scholar
• Doria-Rose, N. A. et al. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature 509, 55–62 (2014).
  CAS PubMed PubMed Central Google Scholar
• Bonsignori, M. et al. Maturation pathway from germline to broad HIV-1 neutralizer of a CD4-mimic antibody. Cell 165, 449–463 (2016).
  CAS PubMed PubMed Central Google Scholar
• Rantalainen, K. et al. Co-evolution of HIV envelope and apex-targeting neutralizing antibody lineage provides benchmarks for vaccine design. Cell Rep. 23, 3249–3261 (2018).
  CAS PubMed PubMed Central Google Scholar
• Landais, E. et al. Broadly neutralizing antibody responses in a large longitudinal Sub-Saharan HIV primary infection cohort. PLoS Pathog. 12, e1005369 (2016).
  PubMed PubMed Central Google Scholar
• Landais, E. et al. HIV Envelope glycoform heterogeneity and localized diversity govern the Initiation and maturation of a V2 apex broadly neutralizing antibody lineage. Immunity 47, 990–1003 (2017).
  CAS PubMed PubMed Central Google Scholar
• Doria-Rose, N. A. et al. New member of the V1V2-directed CAP256-VRC26 lineage that shows increased breadth and exceptional potency. J. Virol. 90, 76–91 (2016).
  CAS PubMed Google Scholar
• Dosenovic, P. et al. Immunization for HIV-1 broadly neutralizing antibodies in human Ig knockin mice. Cell 161, 1505–1515 (2015).
  CAS PubMed PubMed Central Google Scholar
• Escolano, A. et al. Sequential immunization elicits broadly neutralizing anti-HIV-1 antibodies in Ig knockin mice. Cell 166, 1445–1458 (2016).
  CAS PubMed PubMed Central Google Scholar
• Lee, E. C. et al. Complete humanization of the mouse immunoglobulin loci enables efficient therapeutic antibody discovery. Nat. Biotechnol. 32, 356–363 (2014).
  CAS PubMed Google Scholar
• Acharya, P. et al. CD4-binding-site recognition by VH1–46 germline-derived HIV-1 neutralizers. AIDS Res. Hum. Retrov. 30, A120–A121 (2014).
  PubMed Central Google Scholar
• Gorny, M. K. et al. Preferential use of the VH5–51 gene segment by the human immune response to code for antibodies against the V3 domain of HIV-1. Mol. Immunol. 46, 917–926 (2009).
  CAS PubMed Google Scholar
• Huang, C. C. et al. Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120. Proc. Natl Acad. Sci. USA 101, 2706–2711 (2004).
  CAS PubMed PubMed Central Google Scholar
• Baize, S. et al. Emergence of Zaire Ebola virus disease in Guinea. N. Engl. J. Med. 371, 1418–1425 (2014).
  CAS PubMed Google Scholar
• Oswald, W. B. et al. Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog. 3, e9 (2007).
  PubMed PubMed Central Google Scholar
• Qiu, X. et al. Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb. Sci. Rep. 3, 3365 (2013).
  PubMed PubMed Central Google Scholar
• Pettitt, J. et al. Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail. Sci. Transl Med. 5, 199ra113 (2013).
  PubMed Google Scholar
• Murin, C. D. et al. Structures of protective antibodies reveal sites of vulnerability on Ebola virus. Proc. Natl Acad. Sci. USA 111, 17182–17187 (2014).
  CAS PubMed PubMed Central Google Scholar
• Qiu, X. et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514, 47–53 (2014).
  CAS PubMed PubMed Central Google Scholar
• Group, P. I. W. et al. A randomized, controlled trial of ZMapp for ebola virus infection. N. Engl. J. Med. 375, 1448–1456 (2016).
  Google Scholar
• Henao-Restrepo, A. M. et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ca Suffit!). Lancet 389, 505–518 (2017).
  CAS PubMed PubMed Central Google Scholar
• Rimoin, A. W. et al. Ebola virus neutralizing antibodies detectable in survivors of the Yambuku, Zaire outbreak 40 years after infection. J. Infect. Dis. 217, 223–231 (2018).
  CAS PubMed Google Scholar
• Pascal, K. E. et al. Development of clinical-stage human monoclonal antibodies that treat advanced Ebola virus disease in non-human primates. J. Infect. Dis. 218, 612–626 (2018).
  Google Scholar
• Misasi, J. et al. Filoviruses require endosomal cysteine proteases for entry but exhibit distinct protease preferences. J. Virol. 86, 3284–3292 (2012).
  CAS PubMed PubMed Central Google Scholar
• Saphire, E. O. et al. Systematic analysis of monoclonal antibodies against Ebola virus GP defines features that contribute to protection. Cell 174, 938–952 (2018).
  CAS PubMed PubMed Central Google Scholar
• Murphy, A. J. et al. Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. P. Natl Acad. Sci. USA 111, 5153–5158 (2014).
  CAS Google Scholar
• Beniac, D. R. et al. The organisation of Ebola virus reveals a capacity for extensive, modular polyploidy. PLoS ONE 7, e29608 (2012).
  CAS PubMed PubMed Central Google Scholar
• Harris, A. et al. Influenza virus pleiomorphy characterized by cryoelectron tomography. Proc. Natl Acad. Sci. USA 103, 19123–19127 (2006).
  CAS PubMed PubMed Central Google Scholar
• Liu, J., Bartesaghi, A., Borgnia, M. J., Sapiro, G. & Subramaniam, S. Molecular architecture of native HIV-1 gp120 trimers. Nature 455, 109–113 (2008).
  CAS PubMed PubMed Central Google Scholar
• Liu, J., Wright, E. R. & Winkler, H. 3D visualization of HIV virions by cryoelectron tomography. Method Enzymol. 483, 267–290 (2010).
  CAS Google Scholar
• Klein, J. S. & Bjorkman, P. J. Few and far between: How HIV may be evading antibody avidity. PLoS Pathog. 6, e1000908 (2010).
  PubMed PubMed Central Google Scholar
• Galimidi, R. P. et al. Intra-spike crosslinking overcomes antibody evasion by HIV-1. Cell 160, 433–446 (2015).
  CAS PubMed PubMed Central Google Scholar
• Walker, L. M. et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326, 285–289 (2009).
  CAS PubMed PubMed Central Google Scholar
• Scheid, J. F. et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 458, 636–640 (2009).
  CAS PubMed Google Scholar
• Simek, M. D. et al. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J. Virol. 83, 7337–7348 (2009).
  CAS PubMed PubMed Central Google Scholar
• Walker, L. M. et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477, 466–470 (2011).
  CAS PubMed PubMed Central Google Scholar
• Cirelli, K. M. & Crotty, S. Germinal center enhancement by extended antigen availability. Curr. Opin. Immunol. 47, 64–69 (2017).
  CAS PubMed PubMed Central Google Scholar
• Crotty, S. Raging evolution of a B cell response to a viral infection. Nat. Rev. Immunol. 18, 79 (2018).
  CAS PubMed Google Scholar
• Horwitz, J. A. et al. Non-neutralizing antibodies alter the course of HIV-1 infection in vivo. Cell 170, 637–648 (2017).
  CAS PubMed PubMed Central Google Scholar
• Mayr, L., Su, B. & Moog, C. Role of non-neutralizing antibodies in vaccines and/or HIV infected individuals. Curr. Opin. HIV AIDS 12, 209–215 (2017).
  CAS PubMed Google Scholar
• Forthal, D., Hope, T. J. & Alter, G. New paradigms for functional HIV-specific non-neutralizing antibodies. Curr. Opin. HIV AIDS 8, 393–401 (2013).
  PubMed PubMed Central Google Scholar
• Kajihara, M. et al. Inhibition of Marburg virus budding by non-neutralizing antibodies to the envelope glycoprotein. J. Virol. 86, 13467–13474 (2012).
  CAS PubMed PubMed Central Google Scholar
• Bournazos, S. et al. Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. Cell 158, 1243–1253 (2014).
  CAS PubMed PubMed Central Google Scholar
• Bournazos, S. & Ravetch, J. V. Anti-retroviral antibody FcγR-mediated effector functions. Immunol. Rev. 275, 285–295 (2017).
  CAS PubMed PubMed Central Google Scholar
• Bournazos, S. & Ravetch, J. V. Fcγ receptor function and the design of vaccination strategies. Immunity 47, 224–233 (2017).
  CAS PubMed PubMed Central Google Scholar
• Nimmerjahn, F. & Ravetch, J. V. Fcγ receptors: old friends and new family members. Immunity 24, 19–28 (2006).
  CAS PubMed Google Scholar
• Nimmerjahn, F. & Ravetch, J. V. Fc-receptors as regulators of immunity. Adv. Immunol. 96, 179–204 (2007).
  CAS PubMed Google Scholar
• Nimmerjahn, F. & Ravetch, J. V. Fcγ receptors as regulators of immune responses. Nat. Rev. Immunol. 8, 34–47 (2008).
  CAS PubMed Google Scholar
• Pelegrin, M., Naranjo-Gomez, M. & Piechaczyk, M. Antiviral monoclonal antibodies: can they be more than simple neutralizing agents? Trends Microbiol. 23, 653–665 (2015).
  CAS PubMed PubMed Central Google Scholar